Hepatitis C: existing and new treatments

Area of Science:

• Hepatology
• Infectious Diseases
• Pharmacology

Background:

• Hepatitis C virus (HCV) management decisions historically relied on viral genotype and fibrosis, with older treatments like pegylated interferon and ribavirin showing limited efficacy (<50% sustained viral response) and frequent adverse events.
• Prior to 2011, treatment failure left patients with no retreatment options, highlighting a significant unmet need in HCV management.

Purpose of the Study:

• To review the evolution of HCV treatment strategies, focusing on the impact of new direct-acting antiviral (DAA) therapies.
• To evaluate the effectiveness, accessibility, and recommended management protocols for modern HCV treatments.

Main Methods:

• Review of treatment guidelines and clinical research comparing older interferon-based therapies with newer direct-acting antiviral (DAA) regimens.
• Analysis of cure rates, adverse event profiles, treatment duration, and physician management models for HCV infection.

Main Results:

• Direct-acting antivirals (DAAs) have revolutionized HCV treatment, achieving cure rates exceeding 90%, a substantial improvement over previous therapies.
• New DAA regimens are simpler, shorter, and associated with fewer adverse events, leading to updated treatment guidelines.
• HCV treatment is feasible for primary care physicians in collaboration with hepatology specialists, increasing patient access to care.

Conclusions:

• DAAs represent a highly effective and well-tolerated treatment for HCV infection, offering a cure for the vast majority of patients.
• Current guidelines recommend DAA-based regimens, emphasizing the importance of patient counseling on avoiding hepatotoxic substances, pregnancy, and reinfection behaviors.